Legendary Astronaut Dead at 97. He Was Part of Famous Missions
He was a "veteran of the Gemini VII, Gemini XII, and Apollo 8 missions before becoming the Mission Commander for the nearly disastrous Apollo 13 mission to the Moon," according to NASA.
The space agency announced on Aug. 8 that Lovell has died.
James Lovell's Family Confirmed His Death, Expressing Pride Over His Career
NASA released a statement from Lovell's family, confirming his death.
'We are saddened to announce the passing of our beloved father, USN Captain James A. 'Jim' Lovell, a Navy pilot and officer, astronaut, leader, and space explorer. He was 97," the family's statement says.
"We are enormously proud of his amazing life and career accomplishments, highlighted by his legendary leadership in pioneering human space flight. But, to all of us, he was Dad, Granddad, and the Leader of our family.Most importantly, he was our Hero. We will miss his unshakeable optimism, his sense of humor, and the way he made each of us feel we could do the impossible. He was truly one of a kind.'
NASA says, "Captain Lovell was selected as an Astronaut by NASA in September 1962. He has since served as backup pilot for the Gemini 4 flight and backup Commander for the Gemini 9 flight, as well as backup Commander to Neil Armstrong for the Apollo 11 lunar landing mission."
"On December 4, 1965, he and Frank Borman were launched into space on the history-making Gemini 7 mission. The flight lasted 330 hours and 35 minutes and included the first rendezvous of two manned maneuverable spacecraft," the space agency says.
"The Gemini 12 mission, commanded by Lovell with Pilot Edwin Aldrin, began on November 11, 1966. This 4-day, 59-revolution flight brought the Gemini program to a successful close."
Jim Lovell's Wife Marilyn Lovell Preceded Him in Death
A biography of Lovell released by NASA says he was "Born in Cleveland, Ohio, on March 25, 1928. Married to the former Marilyn Gerlach, of Milwaukee, Wisconsin. They have four children."
Lovell's wife Marilyn Lovell died in 2023, according to her obituary.
"On June 6, 1952, Marilyn and Jim married immediately following his graduation at St Anne's Episcopal Church in Annapolis, MD. Jim would proudly tell everyone he, 'married the prettiest girl from Wisconsin!'" the obituary says.
Legendary Astronaut Dead at 97. He Was Part of Famous Missions first appeared on Men's Journal on Aug 8, 2025
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Eating this surprising fruit might be the key to getting a better night's sleep
Eating one avocado a day might be the key to a better night's sleep. Adults who included the fruit -- and yes, it's a fruit -- in their daily diet over the course of just six months reported better quality sleep compared to people who consumed fewer than two avocados each month, researchers said. 'Sleep is emerging as a key lifestyle factor in heart health, and this study invites us to consider how nutrition — and foods like avocado — can play a role in improving it,' Dr. Kristina Petersen, an associate professor of nutritional sciences at Penn State University, explained. The recent findings on sleep were tied to avocado's beneficial nutrients including tryptophan, folate, and magnesium. An essential mineral, magnesium is involved in muscle contraction and relaxation. Tryptophan and folate are involved in producing melatonin, the hormone that regulates our sleep cycles. These conclusions were drawn following an assessment of 969 U.S. adults who had what is considered a larger waistline -- 35 inches or more in women and 40 inches or more in men. The study was supported by the Avocado Nutrition Center, although the agency had no role in data collection, analysis, or interpretation. The researchers had initially intended to focus on heart health alone, before participants reported sleep-related benefits. "This was a cardiovascular health trial, making the sleep benefits more credible since they emerged as unexpected secondary findings in a well-designed randomized controlled trial," Dr. John Saito, a spokesperson for the American Academy of Sleep Medicine and pulmonologist at Children's Hospital of Orange County, told Verywell this week. Eating avocados daily was also associated with a better diet and lower cholesterol levels, the researchers reported, building on similar research from 2022. Studies have previously found that disrupted sleep is linked to high levels of cholesterol: the waxy, fat-like substance that can lead to heart attack and stroke. Improved heart health can help people to get better sleep, and getting enough sleep can also improve heart health and slash the risk of disease, according to the Centers for Disease Control and Prevention. Avocado's healthy fat and fiber contributed to positive cardiovascular impacts. The healthy fat can also help to reduce cholesterol levels, and lower the risk for potentially life-threatening cardiac events. The fiber is tied to a healthy gut and reduced risk of death from any cause. Adults should consume at least 25 grams of fiber each day, according to Harvard Medical School. Of course, healthy fat is still fat, and avocados are packed with both nutrients and calories. An entire large avocado can add upward of 400 calories to your daily diet, the Cleveland Clinic says. But, the fruits are still considered to be healthy when consumed in moderation like being added to a morning smoothie or a salad at lunch. Half an avocado has more potassium than a banana, the Harvard T.H. Chan School of Public Health said. Humans need potassium to help fend off high blood pressure, which can result in kidney disease, eye damage, coronary artery disease, and other complications, if it's left untreated. While the findings of the new study cannot be generalized to all populations, Petersen noted that heart health is influenced by many factors, such as fitness and genetics. 'This is an encouraging step in expanding the science around avocados and the potential benefits of consumption,' she said.
Yahoo
43 minutes ago
- Yahoo
Schrödinger Announces Discontinuation of SGR-2921 Program
NEW YORK, August 14, 2025--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Phase 1 dose-escalation study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Despite early evidence of monotherapy activity observed in the Phase 1 study, based on the profile observed to date, including two emergent events where SGR-2921 was considered to have contributed to two deaths in patients with AML, Schrödinger believes the path to development as a combination therapy would be difficult to pursue. The Phase 1 study was supported by preclinical data which had demonstrated that CDC7 inhibition resulted in monotherapy and combination anti-leukemic responses in patient-derived AML models, suggesting that SGR-2921 could ultimately be used in combination with standard of care agents. "Patient safety is our first priority, and in light of two treatment-related deaths in the Phase 1 dose-escalation study, we have made the decision to discontinue further development of SGR-2921. While disappointing given the early clinical activity observed, we believe this is the right decision for patients," stated Margaret Dugan, M.D., chief medical officer at Schrödinger. "We had hoped to advance this investigational agent for acute myeloid leukemia as relapse rates are high, the disease progresses rapidly and there are limited therapies available. We are very grateful to the investigators, patients and families who have participated in this clinical study." About SchrödingerSchrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit follow us on LinkedIn and Instagram, or visit our blog, Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to the benefits of its computational platform. Statements including words such as "aim," "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goal," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger's current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schrödinger's control, including the uncertainties inherent in drug development, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical and early clinical studies will be predictive of the results of later preclinical studies and clinical trials, whether initial data from clinical results will be predictive of the final results of the clinical trials, uncertainties associated with the regulatory review of clinical trials, and the ability to retain and hire key personnel and other risks detailed under the caption "Risk Factors" and elsewhere in the company's Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission on August 6, 2025, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schrödinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise. View source version on Contacts Jaren Madden (Investors and Media) 617-286-6264 Matthew Luchini (Investors) 917-719-0636 Allie Nicodemo (Media) 617-356-2325
Yahoo
43 minutes ago
- Yahoo
Schrödinger ends development of blood cancer drug after patient deaths
Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial (NCT05961839), SGR-2921 had originally shown activity as a monotherapy; however, the therapy was considered to have contributed to two deaths in patients with relapsed/refractory acute myeloid leukaemia (r/r AML). The trial also enrolled patients with high-risk myelodysplastic syndromes. While these deaths were in patients treated with the drug as a monotherapy, Schrödinger also believes that the path to development as a combination therapy, the original intention, would be difficult to pursue. Schrödinger CMO Dr Margaret Dugan said: 'Patient safety is our first priority, and in light of two treatment-related deaths in the Phase I dose-escalation study, we have made the decision to discontinue further development of SGR-2921. "While disappointing given the early clinical activity observed, we believe this is the right decision for patients. We had hoped to advance this investigational agent for AML as relapse rates are high, the disease progresses rapidly, and there are limited therapies available.' The company's stock opened 12.19% down, from a $19.84 close on 13 August to a $17.42 open on 14 August, shortly after the termination was confirmed. Unmet needs in AML remain There are several unmet needs in AML, especially in patients who experience relapse or do not achieve remission after initial treatment. Current therapeutic options are even more limited for AML patients with relapses. In July 2025, Sellas Life Sciences' CDK9 inhibitor SLS009 (tambiciclib), being used as a triple combination therapy, saw a mean overall response rate (ORR) of 33%, exceeding the threshold of 20%. ORR was the Phase Ia/II trial's primary endpoint. There are several therapies approved r/r AML, including Astella's Xospata (gilteritinib), Agios Pharmaceuticals' Tibsovo (ivosidenib) and Pfizer's Mylotarg (gemtuzumab ozogamicin). However, all of these are for particular mutations of AML. AbbVie's Venclexta (venetoclax) and hypomethylating agent (HMA) combinations are prescribed off-label in this patient population. According to GlobalData, the AML market is set to reach $3.68bn in 2032, across the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). GlobalData is the parent company of Clinical Trials Arena. "Schrödinger ends development of blood cancer drug after patient deaths" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
